Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 66
Filtrar
Más filtros

Bases de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Aliment Pharmacol Ther ; 26(4): 597-603, 2007 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-17661763

RESUMEN

BACKGROUND: Non-cardiac chest pain is an important disorder in Asia. The practice and views of gastroenterologists on non-cardiac chest pain in this region are not known. AIMS: To determine the current understanding, diagnostic practice and treatment strategies among gastroenterologists on the management of non-cardiac chest pain in Asia. METHODS: A 24-item questionnaire was sent to gastroenterologists in Mainland China, Hong Kong, Malaysia, Indonesia, Philippines, Singapore, Taiwan and Thailand. RESULTS: 186 gastroenterologists participated with a response rate of 74%. 98% of gastroenterologists managed patients with non-cardiac chest pain over the last 6 months. 64% felt that the number of non-cardiac chest pain patients was increasing and 85% believed that the most common cause of non-cardiac chest pain was GERD. 94% of the gastroenterologists believed that they should manage non-cardiac chest pain patients, but only 41% were comfortable in diagnosing non-cardiac chest pain. The average number of investigations performed was four in non-cardiac chest pain patients, and oesophago-gastro-duodenoscopy was the most commonly used initial test. A proton pump inhibitor was considered the first-line treatment in non-cardiac chest pain and was reported as the most effective treatment by the gastroenterologists. CONCLUSION: Most gastroenterologists were practicing evidence-based medicine, but frequent use of investigations and a lack of awareness of the role of visceral hypersensitivity in non-cardiac chest pain patients were noted.


Asunto(s)
Antiulcerosos/uso terapéutico , Dolor en el Pecho/terapia , Gastroenterología , Conocimientos, Actitudes y Práctica en Salud , Bombas de Protones/uso terapéutico , Adulto , Asia , Dolor en el Pecho/etiología , Femenino , Reflujo Gastroesofágico/diagnóstico , Reflujo Gastroesofágico/tratamiento farmacológico , Accesibilidad a los Servicios de Salud , Humanos , Masculino , Persona de Mediana Edad , Satisfacción del Paciente , Atención Primaria de Salud , Encuestas y Cuestionarios
2.
Aliment Pharmacol Ther ; 25(4): 463-9, 2007 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-17270002

RESUMEN

BACKGROUND: Tegaserod has been shown to be effective in chronic constipation in Western population. Aim We investigated if tegaserod is equally effective in Chinese population. MATERIALS AND METHODS: Two hundred and fifty patients were randomized to a double-blinded 8-week treatment of tegaserod 6 mg b.d. or placebo. Response during weeks 1-4 was defined as an increase in complete spontaneous bowel motion >/=1/week. Secondary efficacy included response during weeks 1-8, individual symptoms and scores, quality of life and global assessment of bowel habits and constipation. RESULTS: One hundred and nine patients from the treatment group and 107 from the placebo group completed the 8-week treatment. Responder rates was 47.7% vs. 29% for the treatment and placebo groups (P = 0.005). The sustained complete spontaneous bowel motion rate was 29.4% vs. 15.7% in the two groups (P = 0.016). The response rates were higher than that reported previously in the Caucasian studies. There was improvement in the scores for stool form scale, bothersomeness of constipation, abdominal distension/bloating and satisfaction of bowel habit (P < 0.05). The mental score was higher in the treatment group (46.8 +/- 9 vs. 43.6 +/- 10, P = 0.01). CONCLUSIONS: Tegaserod is effective in relieving chronic constipation in Chinese population. The efficacy observed may be higher than that in Western population.


Asunto(s)
Estreñimiento/tratamiento farmacológico , Fármacos Gastrointestinales/uso terapéutico , Indoles/uso terapéutico , Adulto , China , Enfermedad Crónica , Método Doble Ciego , Femenino , Humanos , Masculino , Persona de Mediana Edad , Resultado del Tratamiento
3.
Aliment Pharmacol Ther ; 26(7): 1063-7, 2007 Oct 01.
Artículo en Inglés | MEDLINE | ID: mdl-17877513

RESUMEN

BACKGROUND: The efficacy of levofloxacin-based quadruple therapy in resistant Helicobacter pylori infection is not known. AIM: To test the efficacy of levofloxacin-based quadruple therapy and traditional quadruple therapy in resistant H. pylori infection. METHODS: One hundred and two patients with resistant H. pylori infection were randomized to 1 week of either EBAL (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., amoxicillin 1 g b.d. and levofloxacin 500 mg b.d.) or EBMT (esomeprazole 40 mg b.d., bismuth subcitrate 240 mg b.d., metronidazole 400 mg t.d.s. and tetracycline 500 mg q.d.s.). (13)C-urea breath test was performed at week 12 to assess post-treatment H. pylori status. RESULTS: In intention-to-treat analysis H. pylori eradication was achieved in 37 of 51 (73%) subjects in EBAL and 45 of 51 (88%) subjects in EBMT groups, respectively (P = 0.046). Per-protocol eradication rates of EBAL and EMBT groups were 78% and 94%, respectively (P = 0.030). The intention-to-treat eradication rate was statistically lower for EBAL than EMBT (56% vs. 90%, P = 0.013) among those who had failed more than one course of eradication therapy. Previous levofloxacin triple therapy did not affect the efficacy of either protocol significantly. CONCLUSIONS: Levofloxacin-based quadruple therapy was inferior to traditional quadruple therapy for resistant H. pylori infection.


Asunto(s)
Amoxicilina/uso terapéutico , Antibacterianos/uso terapéutico , Esomeprazol/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Levofloxacino , Ofloxacino/uso terapéutico , Adulto , Anciano , Amoxicilina/farmacología , Antibacterianos/farmacología , Pruebas Respiratorias , Quimioterapia Combinada , Esomeprazol/farmacología , Femenino , Infecciones por Helicobacter/metabolismo , Humanos , Masculino , Persona de Mediana Edad , Ofloxacino/farmacología , Resultado del Tratamiento
4.
Aliment Pharmacol Ther ; 25(9): 1099-104, 2007 May 01.
Artículo en Inglés | MEDLINE | ID: mdl-17439511

RESUMEN

BACKGROUND: Gastro-oesophageal reflux disease and irritable bowel syndrome are common diseases which may be related. AIM: To examine the association between gastro-oesophageal reflux disease and irritable bowel syndrome in Chinese population in Hong Kong. METHODS: Randomly selected ethnic Chinese were invited to participate in a telephone survey in 1996. Gastro-oesophageal reflux disease was defined as subjects having heartburn and/or acid regurgitation once weekly or more. Irritable bowel syndrome was diagnosed according to the Rome I criteria. The association between gastro-oesophageal reflux disease and irritable bowel syndrome was calculated using a statistical model which allows the odds ratio to be measured. RESULTS: One thousand six hundred and forty-nine subjects completed the interview (response rate 62%). The population prevalence of gastro-oesophageal reflux disease and irritable bowel syndrome were 5% and 4%, respectively. Thirteen per cent of subjects with gastro-oesophageal reflux disease and 11% with irritable bowel syndrome suffered from both gastro-oesophageal reflux disease and irritable bowel syndrome. The OR of having gastro-oesophageal reflux disease and irritable bowel syndrome together was estimated to be 3 (95% CI: 1.05, 6.27) indicating a positive association between the two diseases. This association occurred predominantly in male subjects [OR = 9.3, (95% CI: 2.3, 26.2)] but not as strong in females [OR = 1.5, (95% CI: 0.3, 4.3)]. Younger subjects were statistically more prone to the two diseases. CONCLUSIONS: There is a positive association between gastro-oesophageal reflux disease and irritable bowel syndrome, and their association occurs predominantly in male subjects.


Asunto(s)
Reflujo Gastroesofágico/etiología , Síndrome del Colon Irritable/etiología , Adolescente , Adulto , Factores de Edad , Anciano , Ansiedad/complicaciones , China/etnología , Trastorno Depresivo/complicaciones , Femenino , Reflujo Gastroesofágico/etnología , Hong Kong/epidemiología , Humanos , Síndrome del Colon Irritable/etnología , Masculino , Persona de Mediana Edad , Prevalencia , Factores Sexuales , Ausencia por Enfermedad/estadística & datos numéricos , Encuestas y Cuestionarios
5.
Aliment Pharmacol Ther ; 24(8): 1179-86, 2006 Oct 15.
Artículo en Inglés | MEDLINE | ID: mdl-17014576

RESUMEN

BACKGROUND: Safety of traditional Chinese medicine in patients with chronic hepatitis B is unknown. AIM: To study the clinical outcome of traditional Chinese medicine-induced hepatotoxicity in chronic hepatitis B patients. PATIENTS AND METHODS: All chronic hepatitis B patients in 2004 with liver dysfunction requiring hospitalization were screened prospectively for traditional Chinese medicine intake. The hepatotoxicity of individual traditional Chinese medicine elements was determined by extensive search of both English and Chinese publications. RESULTS: Of 45 chronic hepatitis B patients, the liver dysfunction in seven (15.6%) was attributable to traditional Chinese medicine. All had liver dysfunction pattern resembling those of acute exacerbation of chronic hepatitis B. Three patients had adverse outcomes (two deaths, one liver transplantation). One patient had accelerated course of cirrhosis now awaiting liver transplantation. The identified hepatotoxic components were Polygonum multiflorum Thunb, Cassia obtusifolia L, Melia toosendan Sieb., Rheum palmatum L., Scolopendra subspinipes mutilans L, Alisma orientale Juzepe, Glycyrrhiza uralensis Fisch. and Mentha haplocalyx Briq. One traditional Chinese medicine formula was adulterated with a highly hepatotoxic agent, N-nitrosofenfluramine. CONCLUSIONS: Traditional Chinese medicine-related hepatotoxicity resulted in high mortality in chronic hepatitis B patients. Prospective randomized-controlled trials with the same stringent criteria as western medicine clinical trials are required for Chinese medicines, to document their efficacies and safety before they can be advocated for the treatment of patients.


Asunto(s)
Hepatopatías/etiología , Medicina Tradicional China/efectos adversos , Adulto , Medicamentos Herbarios Chinos/efectos adversos , Femenino , Hepatitis B Crónica/tratamiento farmacológico , Humanos , Cirrosis Hepática/etiología , Trasplante de Hígado , Masculino , Persona de Mediana Edad , Estudios Prospectivos , Resultado del Tratamiento
6.
Aliment Pharmacol Ther ; 24(4): 573-83, 2006 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-16907890

RESUMEN

BACKGROUND: Clinical features of hepatocellular carcinoma patients are changing because of screening. AIM: To examine the clinical features of hepatocellular carcinoma patients in Hong Kong and validity of different staging systems. METHODS: A total of 223 Chinese patients with hepatocellular carcinoma were studied. RESULTS: Seventy-eight percent of hepatocellular carcinoma patients had chronic hepatitis B (43% diagnosed by screening). Hepatitis B positivity, weight loss, jaundice, encephalopathy, alpha-fetoprotein level, portal vein thrombosis, extrahepatic metastasis, and treatment were shown to be independent factors affecting survival. Of chronic hepatitis B patients, hepatitis B virus DNA levels (P = 0.001) and portal vein thrombosis (P = 0.008) were independent factors affecting survival. Seventy-six percent of chronic hepatitis B patients with hepatocellular carcinoma were hepatitis B e antigen negative. Screening patients had hepatocellular carcinoma detected at an earlier stage and better survival (median survival: 21 vs. 4 months, P < 0.0001). All staging systems had good stratification of survival. Prognosis and median survival generated were different when compared with the US data. CONCLUSIONS: Chronic hepatitis B was the most common cause of hepatocellular carcinoma in Hong Kong. High-risk chronic hepatitis B patients should be followed irrespective of the hepatitis B e antigen status. Hepatitis B virus DNA levels at the time of diagnosis are an important survival predictor. Screening detected hepatocellular carcinoma at an earlier stage and prolonged survival. Staging systems should be validated in different populations.


Asunto(s)
Carcinoma Hepatocelular/patología , Hepatitis B Crónica/etiología , Adulto , Anciano , Anciano de 80 o más Años , Carcinoma Hepatocelular/etnología , Carcinoma Hepatocelular/virología , China/etnología , Femenino , Hong Kong/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Análisis de Supervivencia
7.
Aliment Pharmacol Ther ; 24(5): 831-6, 2006 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-16918887

RESUMEN

BACKGROUND: We have previously shown reversal of E-cadherin methylation in gastric mucosa from patients with dyspepsia at week 6 after Helicobacter pylori-eradication therapy. But the long-term methylation status of these patients was unknown. AIM: To investigate the methylation status at E-cadherin at year 3 after H. pylori-eradication therapy. METHODS: 35 patients (25 with and 10 without H. pylori eradicated) enrolled in our previous study were recruited into the present study (year 3 analysis). Methylation at E-cadherin was evaluated by methylation-specific polymerase chain reaction method. RESULTS: There was no difference in age and sex distribution in the two groups. Methylation at E-cadherin in patients with H. pylori eradicated at weeks 0, 6 and year 3 were 52%, 20% and 20%, respectively. Concordant methylation status at week 6 and year 3 was 92%. Methylation at E-cadherin in patients without H. pylori at weeks 0, 6 and year 3 were 50%, 60% and 60%, respectively. Concordant methylation status between week 6 and year 3 was 90%. Stability of E-cadherin methylation status was associated with histological changes. No association between E-cadherin methylation status and age was observed. CONCLUSION: The methylation pattern is stable for a long period, thus suggesting the effect of environment on methylation.


Asunto(s)
Cadherinas/metabolismo , Mucosa Gástrica/metabolismo , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Antibacterianos/uso terapéutico , Femenino , Mucosa Gástrica/patología , Infecciones por Helicobacter/metabolismo , Infecciones por Helicobacter/patología , Humanos , Masculino , Metilación , Persona de Mediana Edad , Antro Pilórico/metabolismo , Antro Pilórico/patología
8.
Aliment Pharmacol Ther ; 24(3): 535-9, 2006 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-16886920

RESUMEN

BACKGROUND: Common risk factors exist in colorectal neoplasia (cancer or adenoma) and coronary artery disease. AIM: To investigate in a retrospective study if there is coexistence of the two events in patients > OR =50 years. METHODS: Computer data on colonoscopies performed on symptomatic patients, the corresponding medical record and colonic histology in 1997-2000 were retrieved. History of coronary artery disease was recorded. To adjust for the factors of age and sex, bivariate logistic regression analysis was used to test for coexistence. RESULTS: 1382 patients were recruited. Colorectal neoplasia and history of coronary artery disease were present in 27% (373) and 12% (167) of patients, respectively. The mean age of patients was older in colorectal neoplasia+ (75 +/- 11 vs. 69 +/- 13 years, P < 0.0001) and in coronary artery disease+ (79 +/- 9 vs. 69 +/- 12 years, P < 0.0001) patients. Male was the predominant sex in colorectal neoplasia+: 33% vs. 22% (P < 0.0001), but not in coronary artery disease+ (P = 0.29). Colorectal neoplasia+ patients were more likely to have coronary artery disease+ [21.2% (79/373) vs. 8.8% (89/1098) (P < 0.0001)]. Bivariate logistic regression analysis showed strong association between the two events (OR: 2.12, 95% CI: 1.5, 3.0). CONCLUSION: There is strong coexistence of colorectal neoplasia and coronary artery disease, probably due to exposure to common risk factors.


Asunto(s)
Adenoma/complicaciones , Neoplasias Colorrectales/complicaciones , Enfermedad de la Arteria Coronaria/complicaciones , Anciano , Femenino , Humanos , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Factores de Riesgo
9.
Aliment Pharmacol Ther ; 23(3): 421-7, 2006 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-16423001

RESUMEN

AIM: To test the efficacy of levofloxacin-based second-line therapy for resistant Helicobacter pylori infection. METHODS: One hundred and six patients who failed H. pylori eradication were randomized to receive (i) lansoprazole 30 mg, amoxicillin 1 g, levofloxacin 500 mg, all given twice daily for 7 days (LAL); or (ii) lansoprazole 30 mg twice daily, metronidazole 400 mg thrice daily, bismuth subcitrate 120 mg and tetracycline 500 mg four times daily for 7 days (quadruple). Post-treatment H. pylori status was determined by (13)C-urea breath test. RESULTS: Intention-to-treat and per-protocol H. pylori eradication rates were 57/60% for the LAL group and 71/76% for the quadruple group respectively. Metronidazole, clarithromycin, amoxicillin and levofloxacin resistance were found in 76%, 71%, 0% and 18% of patients, respectively. Levofloxacin resistance led to treatment failure in the LAL group. For patients with dual resistance to metronidazole and clarithromycin, the eradication rates were 79% in the LAL group (levofloxacin-sensitive) and 65% in the quadruple group (P=0.34). CONCLUSION: Lansoprazole, amoxicillin plus levofloxacin second-line therapy is comparable with quadruple therapy in efficacy. Subjects, especially those with dual resistance to metronidazole and clarithromycin, may consider levofloxacin-based therapy for levofloxacin-sensitive strains.


Asunto(s)
Antiinfecciosos/uso terapéutico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , 2-Piridinilmetilsulfinilbencimidazoles , Adulto , Anciano , Amoxicilina/uso terapéutico , Antibacterianos/uso terapéutico , Farmacorresistencia Bacteriana , Quimioterapia Combinada , Femenino , Hong Kong , Humanos , Lansoprazol , Levofloxacino , Masculino , Metronidazol/uso terapéutico , Persona de Mediana Edad , Ofloxacino/uso terapéutico , Omeprazol/análogos & derivados , Omeprazol/uso terapéutico , Compuestos Organometálicos , Tetraciclina/uso terapéutico , Resultado del Tratamiento
11.
Aliment Pharmacol Ther ; 21(1): 83-9, 2005 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-15644049

RESUMEN

BACKGROUND: The performance of commercial Helicobacter pylori diagnostic kits developed for particular geographic regions has often been found to be of poor diagnostic value when applied to other regions, possibly because of infections being caused by different H. pylori strains in different regions. AIM: To evaluate the performance of an IgG2 anti-H. pylori enzyme-linked immunoassay test (Helirad Alert) for detection of H. pylori infection in both Australian and Hong Kong (Chinese) subjects. METHODS: Serum samples were tested for H. pylori specific IgG2 and IgG antibodies by enzyme-linked immunoassay kits using identical antigen preparation in 168 Australian and 160 Hong Kong (Chinese) subjects diagnosed with dyspepsia. RESULTS: Using a cut-off value determined by analysis of H. pylori-negative Australian samples, the sensitivity, specificity and accuracy of the IgG2 assay were 77.8, 97.4 and 91.1%, respectively, for the Australian samples and 96.3, 83.8 and 90% for Hong Kong samples. For the IgG assay, sensitivity, specificity and accuracy were 87.0, 99.1 and 95.2% for Australian samples and 97.5, 75 and 86.3% for Hong Kong samples respectively. Receiver-operating characteristic analysis showed better discrimination of H. pylori status when the IgG2 assay was applied to Hong Kong samples, while the IgG assay was better in the Australian samples. CONCLUSION: These data demonstrate that the Helirad Alert enzyme-linked immunoassay could provide a reliable method for screening H. pylori infection in both western and Chinese populations.


Asunto(s)
Anticuerpos Antibacterianos/sangre , Infecciones por Helicobacter/diagnóstico , Helicobacter pylori/inmunología , Inmunoglobulina G/sangre , Adulto , Anciano , Anciano de 80 o más Años , Pueblo Asiatico/etnología , Ensayo de Inmunoadsorción Enzimática/métodos , Ensayo de Inmunoadsorción Enzimática/normas , Femenino , Infecciones por Helicobacter/etnología , Hong Kong/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Nueva Gales del Sur/epidemiología , Sensibilidad y Especificidad , Población Blanca/etnología
12.
Aliment Pharmacol Ther ; 21(7): 841-9, 2005 Apr 01.
Artículo en Inglés | MEDLINE | ID: mdl-15801919

RESUMEN

BACKGROUND: Long-term effect of YMDD mutations on liver histology in Chinese hepatitis B patients is unknown. AIM: To examine the effect of prolonged lamivudine treatment on liver histology in Chinese patients with and without YMDD mutations. METHODS: Liver histology was assessed in 85 patients on long-term lamivudine at baseline and year 1, and at year 3 for 25 patients. RESULTS: Comparing patients with and without YMDD mutations at year 1, the former had higher baseline median necroinflammatory (11 vs. six respectively, P = 0.014) and fibrosis scores (three vs. one respectively, P = 0.001). The proportion of patients with improvement in necroinflammation and worsening of fibrosis was comparable for patients with and without YMDD mutations at year 1 (57.1%, 14.3% vs. 55%, 15% respectively) and year 3 (57.9%, 26.3% vs. 50%, 16.7% respectively). Comparing the histology at year 1 and 3, more patients with YMDD mutations developing after year 1 had worsening of necroinflammation than patients with persistent YMDD wild type (53.8% vs. 25% respectively). CONCLUSIONS: Patients who developed YMDD mutations had higher baseline histological scores. With YMDD mutations, the liver histology became less favourable after 3 years than at the first year, although there was still improvement when compared with that at baseline.


Asunto(s)
Pueblo Asiatico/genética , Hepatitis B Crónica/tratamiento farmacológico , Lamivudine/uso terapéutico , Hígado/patología , Inhibidores de la Transcriptasa Inversa/uso terapéutico , Adolescente , Adulto , Biopsia/métodos , China/etnología , ADN Viral/genética , Femenino , Virus de la Hepatitis B/genética , Hepatitis B Crónica/etnología , Hepatitis B Crónica/patología , Humanos , Cirrosis Hepática/patología , Cirrosis Hepática/virología , Masculino , Persona de Mediana Edad , Mutación/genética
13.
Aliment Pharmacol Ther ; 22(5): 483-8, 2005 Sep 01.
Artículo en Inglés | MEDLINE | ID: mdl-16128687

RESUMEN

BACKGROUND: Functional constipation is a common problem in clinical practice. No validated questionnaire is available in Chinese. AIM: To develop a validated questionnaire for diagnosis and symptom assessment in functional constipation for the Chinese population. METHODS: One hundred and eleven patients with constipation and 110 healthy controls were presented with a 24-item constipation questionnaire in the Chinese language. Quality of life in constipation patients was assessed by Short Form-36. Polyethylene glycol was prescribed, for 4 weeks, to 20 patients with newly diagnosed constipation. The questionnaire was administered before and 4 weeks after treatment. Concept, content, construct, discriminant validity and reliability of the questionnaire were assessed. RESULTS: Six items were selected by logistic regression to account for most of the differences between controls and constipated patients with a good reproducibility and internal consistency. A cut-off score of > or =5 was determined to discriminate between controls and constipated patients with a sensitivity of 91% and a specificity of 91%. The constipation questionnaire correlated negatively with seven domains of the Short Form-36 and discriminated between constipated patients who reported symptomatic improvement during polyethylene glycol treatment. CONCLUSIONS: The Chinese constipation questionnaire could be used in epidemiological studies to assess the frequency and severity of constipation in patient populations and in interventional studies of constipation.


Asunto(s)
Estreñimiento/diagnóstico , Encuestas y Cuestionarios/normas , Adolescente , Adulto , Anciano , Pueblo Asiatico , Niño , Femenino , Humanos , Masculino , Persona de Mediana Edad , Calidad de Vida , Sensibilidad y Especificidad
14.
Aliment Pharmacol Ther ; 22(3): 243-9, 2005 Aug 01.
Artículo en Inglés | MEDLINE | ID: mdl-16091062

RESUMEN

BACKGROUND: Peptic ulcer disease is mainly caused by Helicobacter pylori infection and the use of non-steroidal anti-inflammatory drugs. AIM: To investigate the trends in the prevalence of peptic ulcer disease, H. pylori infection and non-steroidal anti-inflammatory drug use in uninvestigated dyspeptic patients over recent years in Hong Kong. METHODS: Data from consecutive patients with uninvestigated dyspeptic symptoms referred by family physicians for open access upper endoscopy during 1997 and 2003 were analysed in relation to peptic ulcer disease, H. pylori infection and non-steroidal anti-inflammatory drug use. RESULTS: Among 2700 patients included, 405 (15%) had peptic ulcer disease and 14 (0.5%) had gastric cancer. There was a reduced trend from 1997 to 2003 in the prevalence of peptic ulcer disease (17, 20, 14, 16, 13, 14 and 14%, respectively, chi2 = 5.80, P = 0.016) (mainly because of decrease in duodenal ulcers), H. pylori infection (44, 50, 49, 44, 40, 40, 36 and 43%, respectively, chi2 = 13.55, P < 0.001) and non-steroidal anti-inflammatory drug use (13, 5, 5, 6, 3, 4, 4 and 5% respectively, chi2 = 13.61, P < 0.001). The prevalence of peptic ulcer disease, H. pylori infection and non-steroidal anti-inflammatory drug use between 2001 and 2003 were significantly lower than that between 1997 and 2000 (17% vs. 13%, OR = 0.78, 95% CI: 0.63-0.96, P = 0.020 for peptic ulcer disease; 47% vs. 39%, OR =0.72, 95% CI: 0.60-0.86, P < 0.001 for H. pylori infection; and 6% vs. 4%, OR = 0.56, 95% CI: 0.39-0.82, P = 0.002 for non-steroidal anti-inflammatory drug use). H. pylori infection was associated with both duodenal ulcer (OR = 15.87, 95% CI: 10.60-23.76, P < 0.001) and gastric ulcer (OR = 3.12, 95% CI: 2.15-4.53, P < 0.001) whereas non-steroidal anti-inflammatory drug use was only associated with gastric ulcer (OR = 2.97, 95% CI: 1.70-5.20, P < 0.001). CONCLUSIONS: The prevalence of peptic ulcer disease, mainly duodenal ulcers, was reduced in association with a decreasing trend in the prevalence of H. pylori infection and non-steroidal anti-inflammatory drug use from 1997 to 2003.


Asunto(s)
Dispepsia/epidemiología , Infecciones por Helicobacter/epidemiología , Helicobacter pylori , Úlcera Péptica/epidemiología , Adolescente , Adulto , Factores de Edad , Anciano , Anciano de 80 o más Años , Antiinflamatorios no Esteroideos/administración & dosificación , Antiinflamatorios no Esteroideos/efectos adversos , Úlcera Duodenal/epidemiología , Úlcera Duodenal/microbiología , Dispepsia/microbiología , Medicina Familiar y Comunitaria , Femenino , Infecciones por Helicobacter/complicaciones , Hong Kong/epidemiología , Humanos , Masculino , Persona de Mediana Edad , Úlcera Péptica/microbiología , Prevalencia , Derivación y Consulta , Factores Sexuales , Neoplasias Gástricas/epidemiología , Neoplasias Gástricas/microbiología
15.
Aliment Pharmacol Ther ; 21(1): 73-81, 2005 Jan 01.
Artículo en Inglés | MEDLINE | ID: mdl-15644048

RESUMEN

BACKGROUND: Recent studies suggest that the Helicobacter pylori eradication rate in patients with non-ulcer dyspepsia is lower when compared to patients with peptic ulcer diseases. AIM: The aim of this study was to study the efficacy of triple therapy for H. pylori infection in patients with duodenal ulcer vs. patients with non-ulcer dyspepsia. METHODS: A total of 582 Chinese patients with proven H. pylori infection were recruited to receive: omeprazole 20 mg, amoxicillin 1000 mg and clarithromycin 500 mg all given twice daily for 7 days (OCA regime). Endoscopy with rapid urease test, histology and culture were performed before treatment. Post-treatment H. pylori status was determined by (13)C-urea breath test. Metronidazole, clarithromycin and amoxicillin resistance was defined as minimum inhibitory concentration (MIC) of >8 microg/mL, >1 microg/mL and >1 microg/mL, respectively. RESULTS: A significantly higher (intention-to-treat/per-protocol) eradication rate was found in patients with duodenal ulcer than those with non-ulcer dyspepsia (91/94% vs. 84/88% respectively, P = 0.011 and P = 0.016). Clarithromycin resistance rate was higher in patients with non-ulcer dyspepsia than those with duodenal ulcer (14% vs. 6%, P = 0.015). Clarithromycin resistance (40% vs. 5%, P < 0.001, OR 12, 95% CI: 5.7-24.3) and the diagnosis of non-ulcer dyspepsia (91% vs. 84%, P = 0.011, OR 2.0, 95% CI: 1.2-3.3) significantly affected the success of H. pylori eradication. CONCLUSION: Clarithromycin resistance accounts for the significantly lower and suboptimal H. pylori eradication rate of OCA regimen in Chinese patients with non-ulcer dyspepsia compared to those with duodenal ulcer.


Asunto(s)
Quimioterapia Combinada/uso terapéutico , Úlcera Duodenal/microbiología , Dispepsia/microbiología , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Adolescente , Adulto , Anciano , Amoxicilina/uso terapéutico , Antiulcerosos/uso terapéutico , Pueblo Asiatico/etnología , Claritromicina/uso terapéutico , Resistencia a Medicamentos , Úlcera Duodenal/etnología , Dispepsia/etnología , Femenino , Infecciones por Helicobacter/etnología , Humanos , Masculino , Metronidazol/uso terapéutico , Persona de Mediana Edad , Omeprazol/uso terapéutico , Cooperación del Paciente , Resultado del Tratamiento
16.
Eur J Cancer Prev ; 14(2): 181-4, 2005 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-15785323

RESUMEN

Colorectal cancer is the second commonest cancer in Hong Kong. The screening behaviour of the Chinese population has not been assessed. The aim of this study is to report a pilot study of educating and subsequent evaluation of colorectal cancer screening behaviour in the Hong Kong Chinese population. Subjects were invited to attend a free health talk on colorectal cancer. Both self-paid faecal occult blood testing (FOBT) and free screening colonoscopy were offered after the education programme. Of the participants taking part in the education programme 113/119 (95%) completed the FOBT. Of the FOBT 8/113 (7%) showed positive result and three patients had neoplasia at colonoscopy. Twenty-five patients with negative FOBT also completed colonoscopy; two had adenomas. Screening colonoscopy after FOBT was accepted by 28% of subjects. Those younger than 65 years and those with a positive FOBT (7/8 versus 25/105 for those with negative FOBT, P=0.0003) were more likely to agree to screening colonoscopy. In conclusion, health education is important for ensuring high acceptance and implementation of colorectal cancer screening in Hong Kong Chinese. FOBT is an acceptable and feasible screening method in Hong Kong.


Asunto(s)
Neoplasias del Colon/diagnóstico , Colonoscopía/estadística & datos numéricos , Sangre Oculta , Cooperación del Paciente , Educación del Paciente como Asunto , Anciano , Femenino , Conductas Relacionadas con la Salud , Hong Kong , Humanos , Masculino , Persona de Mediana Edad
17.
Zhonghua Zhong Liu Za Zhi ; 27(3): 145-7, 2005 Mar.
Artículo en Zh | MEDLINE | ID: mdl-15946562

RESUMEN

OBJECTIVE: To investigate the underlying mechanism of apoptosis-inducing effect of a specific COX-2 inhibitor SC236 in gastric cancer cells. METHODS: Western blot analysis was used to measure apoptosis-related proteins, cytochrome c, and caspase-3. The catalytic activity of the caspases was measured using a colorimetric assay. RESULTS: Treatment of AGS gastric cancer cells with SC236 caused a significant elevation of the pro-apoptotic protein Bak, release of cytochrome c to the cytosol, and activation of caspase-3. A specific caspase-3 inhibitor, z-DEVD-fmk, blocked SC236-induced apoptosis. CONCLUSION: SC236 inhibits cell growth and induces apoptosis in gastric cancer cells at least partly through the up-regulation of Bak, stimulation of cytochrome c release, and activation of caspase-3.


Asunto(s)
Apoptosis/efectos de los fármacos , Inhibidores de la Ciclooxigenasa 2/farmacología , Pirazoles/farmacología , Neoplasias Gástricas/patología , Sulfonamidas/farmacología , Proteína Destructora del Antagonista Homólogo bcl-2/metabolismo , Adenocarcinoma/metabolismo , Adenocarcinoma/patología , Caspasa 3 , Caspasas/metabolismo , Línea Celular Tumoral , Citocromos c/metabolismo , Humanos , Oligopéptidos/farmacología , Poli(ADP-Ribosa) Polimerasas/metabolismo , Neoplasias Gástricas/metabolismo
18.
Aliment Pharmacol Ther ; 19(3): 359-65, 2004 Feb 01.
Artículo en Inglés | MEDLINE | ID: mdl-14984383

RESUMEN

BACKGROUND: Clopidogrel causes significantly less symptomatic peptic ulcer disease and gastrointestinal bleeding than low-dose aspirin in average-risk patients. The gastrotoxicity of clopidogrel in patients with active peptic ulcer disease is unknown. AIM: To compare the incidence of unhealed ulcers in patients receiving clopidogrel or aspirin. METHODS: Patients with aspirin-induced peptic ulcer disease treated with omeprazole (20 mg/day) were randomized to receive clopidogrel (75 mg/day) or to continue with low-dose aspirin. Success was defined as ulcer/erosion healing at the eighth week. RESULTS: One hundred and twenty-nine patients were recruited (69 received clopidogrel and 60 continued with aspirin). Thirty-one (45%) in the clopidogrel group and 25 (42%) in the aspirin group had a minor gastrointestinal bleed. No ulcer showed an adherent clot or visible vessel. The distributions of peptic ulcer disease were similar in the clopidogrel and aspirin groups (gastric ulcer: 41% vs. 40%; duodenal ulcer: 10% vs. 12%; gastric ulcer + duodenal ulcer: 6% vs. 3%; gastritis: 32% vs. 37%; duodenitis: 4% vs. 7%; gastritis + duodenitis: 0% vs. 2%). Clopidogrel and aspirin were re-started after 0.86 +/- 1.79 and 0.44 +/- 1.60 days, respectively (P = 0.170). Three (4%) patients stopped clopidogrel due to drug rash. Using per protocol analysis, the treatment success rates of clopidogrel and aspirin were 94% (62/66) and 95% (57/60), respectively. CONCLUSIONS: In patients with aspirin-associated peptic ulcer disease of low to moderate grade, both early conversion from aspirin to clopidogrel and continuation of aspirin are safe.


Asunto(s)
Antiulcerosos/administración & dosificación , Aspirina/efectos adversos , Omeprazol/administración & dosificación , Úlcera Péptica Hemorrágica/inducido químicamente , Úlcera Péptica/inducido químicamente , Ticlopidina/análogos & derivados , Ticlopidina/administración & dosificación , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Aspirina/administración & dosificación , Clopidogrel , Femenino , Humanos , Masculino , Persona de Mediana Edad , Úlcera Péptica/tratamiento farmacológico , Úlcera Péptica Hemorrágica/tratamiento farmacológico , Factores de Riesgo , Método Simple Ciego
19.
Aliment Pharmacol Ther ; 19(4): 401-6, 2004 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-14871279

RESUMEN

BACKGROUND: Hepatitis B virus infection is an important aetiological factor for hepatocellular carcinoma. Clusters of hepatocellular carcinoma have been observed in families infected with hepatitis B virus. AIM: To investigate the prevalence and characteristics of hepatocellular carcinoma associated with familial hepatitis B virus in Hong Kong. METHODS: Hepatitis B virus patients were screened for familial hepatocellular carcinoma using a standardized questionnaire. The clinical features of patients with familial hepatocellular carcinoma were compared with those of 118 patients with sporadic hepatocellular carcinoma attending the clinic during the same period. RESULTS: A total of 5080 patients were interviewed. Validation of the questionnaire indicated that the reliability was high. There were 22 families with familial hepatocellular carcinoma, giving a prevalence of 4.3 families/1000 hepatitis B virus carriers. The mean age of onset was 48.5 +/- 13 years in familial hepatocellular carcinoma and 62 +/- 11 years in sporadic hepatocellular carcinoma (P = 0.005). The ages of onset were 59 +/- 11, 40 +/- 10 and 18 +/- 4 years in the first, second and third generations, respectively (P < 0.0001), suggesting an anticipation phenomenon. Familial hepatocellular carcinoma patients were more likely to present with pain (70% vs. 10%, P < 0.0001), but not on routine screening (14% vs. 52%, P < 0.0001), than sporadic hepatocellular carcinoma patients. CONCLUSION: The prevalence of familial hepatocellular carcinoma is significant in Hong Kong. These patients show specific clinical features when compared with patients with sporadic hepatocellular carcinoma.


Asunto(s)
Carcinoma Hepatocelular/genética , Hepatitis B Crónica/genética , Neoplasias Hepáticas/genética , Adolescente , Adulto , Edad de Inicio , Anciano , Carcinoma Hepatocelular/epidemiología , Carcinoma Hepatocelular/virología , Composición Familiar , Femenino , Hepatitis B Crónica/complicaciones , Hepatitis B Crónica/epidemiología , Hong Kong/epidemiología , Humanos , Pruebas de Función Hepática , Neoplasias Hepáticas/epidemiología , Neoplasias Hepáticas/virología , Masculino , Persona de Mediana Edad , Linaje , Prevalencia
20.
Aliment Pharmacol Ther ; 17(2): 289-96, 2003 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-12534415

RESUMEN

BACKGROUND: There is some uncertainty as to whether high-risk patients with difficult common bile duct stones should be subjected to a further endoscopic procedure for the complete removal of stones by electrohydraulic lithotripsy or whether permanent biliary stenting should be performed. AIM: To compare the outcome of permanent biliary stenting with electrohydraulic lithotripsy in this group of patients. METHODS: In a prospective study, 36 patients with difficult common bile duct stones were investigated: 19 underwent double pigtail insertion (stent group), whereas 17 underwent complete clearance of stones (electrohydraulic lithotripsy). RESULTS: In the electrohydraulic lithotripsy group, successful stone clearance was achieved in 76.5%, whereas, in the stent group, the success of stenting was 94.7%. A significant difference was detected in the actuarial incidence of recurrent acute cholangitis when the electrohydraulic lithotripsy group was compared with the stent group [one patient (7.7%) vs. 12 patients (63.2%), respectively; P = 0.002, log rank test]. A significant difference was detected in the actuarial frequency of mortality between the electrohydraulic lithotripsy and stent groups [seven patients (41.2%) vs. 14 patients (73.7%), respectively; P = 0.01, log rank test]. CONCLUSIONS: The removal of difficult common bile duct stones by electrohydraulic lithotripsy and further endoscopic retrograde cholangiopancreatography has a high success rate and a low complication rate even in the elderly.


Asunto(s)
Colangiopancreatografia Retrógrada Endoscópica/métodos , Cálculos Biliares/terapia , Litotricia/métodos , Stents , Anciano , Anciano de 80 o más Años , Colangiopancreatografia Retrógrada Endoscópica/efectos adversos , Colangitis/etiología , Femenino , Estudios de Seguimiento , Humanos , Masculino , Recurrencia , Stents/efectos adversos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA